Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Salicylic acid: an old dog, new tricks, and staphylococcal disease
Mathias Herrmann
Mathias Herrmann
Published July 15, 2003
Citation Information: J Clin Invest. 2003;112(2):149-151. https://doi.org/10.1172/JCI19143.
View: Text | PDF
Commentary

Salicylic acid: an old dog, new tricks, and staphylococcal disease

  • Text
  • PDF
Abstract

Aspirin has been shown to cause a reduction in the virulence of Staphylococcus aureus–associated endocarditis. A new study reveals that salicylic acid, the major metabolite of aspirin, acts at the level of transcription to downregulate the production of fibrinogen, fibronectin, and α-hemolysin — virulence factors necessary for bacterial replication in host tissues and, now, potential therapeutic targets.

Authors

Mathias Herrmann

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Pathogenic events resulting in endovascular disease. Local inflammation ...
Pathogenic events resulting in endovascular disease. Local inflammation activates the binding of fibronectin by ECs through vascular cell adhesion molecules; platelet activation is triggered by cytokines and tissue factor (TF) secreted by monocytes and ECs. Fibronectin also mediates invasion of ECs by S. aureus, allowing for persistence and intracellular growth shielded from host defense. The inflammatory response mediated by T cells and polymorphonuclear neutrophils (PMNs) may be mitigated by the effect of Eap (39, 40). MO, monocyte.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts